These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35393854)
1. Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology. Kelley RF; Tesar DB; Wang Y; Agard NJ; Holder PG; Chan J; Comps-Agrar L; Horvath J; Horvath JD; Crowell SR Mol Pharm; 2022 May; 19(5):1540-1547. PubMed ID: 35393854 [TBL] [Abstract][Full Text] [Related]
2. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925 [TBL] [Abstract][Full Text] [Related]
3. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model. Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810 [TBL] [Abstract][Full Text] [Related]
4. Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration. Kaiser PK; Giani A; Fuchs H; Chong V; Heier JS Ophthalmic Res; 2023; 66(1):653-663. PubMed ID: 36626895 [TBL] [Abstract][Full Text] [Related]
5. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S; Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618 [TBL] [Abstract][Full Text] [Related]
6. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C; Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713 [TBL] [Abstract][Full Text] [Related]
7. Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. Bantseev V; Horvath J; Barteselli G; Ranade S; Maia M; Yadav DB; Schuetz C; Shelton A; Booler HS Toxicol Pathol; 2021 Apr; 49(3):663-672. PubMed ID: 33205714 [TBL] [Abstract][Full Text] [Related]
8. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
9. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration. Feng L; Hu JH; Chen J; Xie X J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508 [TBL] [Abstract][Full Text] [Related]
10. Wet age-related macular degeneration: treatment advances to reduce the injection burden. Baumal CR Am J Manag Care; 2020 May; 26(5 Suppl):S103-S111. PubMed ID: 32479026 [TBL] [Abstract][Full Text] [Related]
14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Ferro Desideri L; Barra F; Ferrero S; Traverso CE; Nicolò M Expert Opin Biol Ther; 2019 Aug; 19(8):735-751. PubMed ID: 31180279 [No Abstract] [Full Text] [Related]
16. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
17. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. Tesar D; Luoma J; Wyatt EA; Shi C; Shatz W; Hass PE; Mathieu M; Yi L; Corn JE; Maass KF; Wang K; Dion MZ; Andersen N; Loyet KM; van Lookeren Campagne M; Rajagopal K; Dickmann L; Scheer JM; Kelley RF MAbs; 2017; 9(8):1297-1305. PubMed ID: 28854082 [TBL] [Abstract][Full Text] [Related]
18. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K; Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856 [TBL] [Abstract][Full Text] [Related]
19. Aflibercept in wet AMD: specific role and optimal use. Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705 [TBL] [Abstract][Full Text] [Related]
20. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]